Eye Care Benefits of Anti-Aging Compound Capsules in Healthy Adults (Eye Care)
Exploring the Eye Care Benefits of Anti-aging Compound Capsules
This study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Participants will consume anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for four weeks.
The primary outcome is the improvement of ocular discomfort and eye fatigue symptoms assessed using the Ocular Surface Disease Index (OSDI). Secondary outcomes include visual acuity, accommodative function, tear film stability, macular pigment optical density, intraocular pressure, and photostress recovery time. The study will investigate whether daily supplementation with anti-aging compound capsules can improve visual comfort and support ocular health.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Visual fatigue and ocular discomfort have become increasingly prevalent due to prolonged use of digital devices, environmental stressors, and age-related changes in visual function. Nutritional supplementation containing antioxidants, carotenoids, omega-3 fatty acids, vitamins, minerals, and other bioactive compounds may help maintain ocular health and visual performance.
This prospective, single-arm, open-label clinical study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Twenty-five participants will be enrolled and instructed to consume anti-aging compound capsules for four consecutive weeks.
Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters.
Participants will consume two capsules twice daily for a total daily intake of 2,200 mg. Ophthalmic assessments will be performed at baseline, Week 2, and Week 4.
The primary outcome measure is the Ocular Surface Disease Index (OSDI) score. Secondary outcome measures include distance visual acuity, near visual acuity, accommodative response, accommodative facility, tear film break-up time, macular pigment optical density, intraocular pressure, and photostress recovery time.
The study aims to determine whether supplementation with anti-aging compound capsules can improve eye fatigue symptoms and support ocular health in healthy adults.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Taichung, Tchaj-wan
- Department of Optometry, Chung Shan Medical University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Adults aged 20 to 60 years. Willing to participate in the study and able to provide written informed consent.
Spherical equivalent refractive error less than 700 diopters of myopia (i.e., < -7.00 D).
Exclusion Criteria:
- Regular consumption within the past 1 month of dietary supplements primarily indicated for eye health, or products containing active ocular health-related ingredients that may influence study outcomes (e.g., high-dose lutein ≥10 mg/day or zeaxanthin ≥2 mg/day). Use of general multivitamins or non-eye-specific supplements containing low-dose related ingredients (≤2 mg) may be allowed at the discretion of the investigators.
History of ocular infection or ocular surgery within the past 3 months. Clinically diagnosed ocular diseases, including but not limited to glaucoma, cataract, age-related macular degeneration, or diabetic retinopathy, or a history of ocular procedures such as cataract surgery, retinal laser therapy, or refractive surgery (e.g., LASIK).
Known or self-reported hypersensitivity or allergic reaction to any component of the investigational product, including but not limited to fish oil, soybean-derived products, gelatin (bovine source), yeast, or any other listed ingredients.
Individuals with direct affiliation, supervisory, evaluative, or dependent relationships with the research team, including but not limited to:
Students taught, supervised, or evaluated by members of the research team; Laboratory or research assistants, staff, or collaborators within the same research unit; Interns, part-time workers, or employees under the supervision of the research team.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Anti-Aging Compound Capsules
Participants will receive anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for 4 weeks.
Participants will take 2 capsules twice daily (total daily dose 2,200 mg).
|
Participants will consume anti-aging compound capsules twice daily for 4 weeks.
Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters.
Total daily intake is 2,200 mg.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Ocular Surface Disease Index (OSDI) Score
Časové okno: baseline / week2 / week4
|
Changes in ocular discomfort and eye fatigue symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire.
The OSDI is a validated 12-item questionnaire used to evaluate symptoms related to ocular surface disease and visual function.
Assessments will be performed at baseline, Week 2, and Week 4. A decrease in OSDI score indicates improvement in ocular symptoms.
|
baseline / week2 / week4
|
|
Change in Distance Visual Acuity (DVA, logMAR)
Časové okno: baseline / week2 / week4
|
Changes in distance visual acuity will be measured using a Snellen chart at 6 meters and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis.
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Near Visual Acuity (NVA)
Časové okno: baseline / week2 / week4
|
Changes in near visual acuity will be assessed using a Snellen near-vision chart at a distance of 40 cm.
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Accommodative Response
Časové okno: baseline / week2 / week4
|
Accommodative response will be measured using a Shin-Nippon NVision-K5001 open-field autorefractor, including accommodative lag and accommodative lead.
Measurements will be conducted at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Accommodative Facility (cycles per minute)
Časové okno: baseline / week2 / week4
|
Accommodative facility will be assessed using ±0.50 diopter flipper lenses with standard accommodative targets.
Results will be recorded as cycles per minute (CPM).
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Tear Film Break-Up Time (TBUT)
Časové okno: baseline / week2 / week4
|
Tear film stability will be evaluated using non-invasive tear break-up time measured by a corneal topography system (Topcon CA-800).
Assessments will be conducted at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Macular Pigment Optical Density (MPOD)
Časové okno: baseline / week2 / week4
|
Macular pigment optical density will be measured using a macular pigment optical density analyzer.
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Photostress Recovery Time
Časové okno: baseline / week2 / week4
|
Photostress recovery time will be assessed by measuring the time required for visual function to return to baseline following exposure to a standardized bright light stimulus.
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Intraocular Pressure (IOP)
Časové okno: baseline / week2 / week4
|
Intraocular pressure will be measured using non-contact tonometry.
Measurements will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Lin, associated professor, Institute of Medical Research, Chung Shan Medical University
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CS1-25234
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Únava očí
-
Aydin Adnan Menderes UniversityDokončenoVzdělávání ošetřovatelství | Simulační trénink | Eye TrackerKrocan
-
Yu-Hsin HsiehChang Gung University; Jonkoping University; Folke Bernadotte Stiftelsen; Stiftelsen... a další spolupracovníciDokončenoPoruchy komunikace | Svépomocná zařízení | Technologie Eye-Gaze | Těžká tělesná postiženíŠvédsko
-
Peking UniversityNeznámýMelanom (kůže) | Bazaliom | Spinocelulární karcinom in situ | Oční nádor | Melanom na místě | Nevus Eye | Karcinom mazové žlázy očního víčka